The association of parathyroid hormone with ESRD and pre-ESRD mortality in the kidney early evaluation program

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4414-4421

  Saab, Georges ^a,b   Bomback, Andrew S ^c   McFarlane, Samy I ^d   Li, Suying ^e   Chen, Shu Cheng ^e   McCullough, Peter A ^f,g,h   Whaley Connell, Adam ^i,j  

^a METROHEALTH MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^f St John Providence Health System   (United States)

^g PROVIDENCE HOSPITAL   (United States)

^h Providence Park Heart Institute   (United States)

ⁱ University of Missouri   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; GOVERNMENT; HEALTH PROGRAM; HIGH SCHOOL; HUMAN; HYPERTENSION; KIDNEY EARLY EVALUATION PROGRAM; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEGRO; PRIORITY JOURNAL; SURVIVAL;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84870735509     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2001     Document Type: Article

References (41)

1. GoAS, ChertowGM,Fan D, McCulloch CE, Hsu CY 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305
2. Kumar R, Thompson JR 2011 The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 22:216-224
3. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL 2009 Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 53:S3-S10
4. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A 2012 Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol 44: 541-547
5. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K 2008 Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73:1296-1302 (Pubitemid 351693159)
6. Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K 2009 Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract 113:c54-c61
7. Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, Siscovick D, Kestenbaum B 2011 Vitamin D, parathyroid hormone, and sudden cardiac death. Hypertension 58:1021-1028
8. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J 2009 Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119:2765-2771
9. Guo Y, Yuan W, Wang L, Shang M, Peng Y 2011 Parathyroid hormone-potentiated connective tissue growth factor expression in human renal proximal tubular cells through activating the MAPK and NF-κB signalling pathways. Nephrol Dial Transplant 26:839-847
10. Ogata H, Ritz E, Odoni G, Amann K, Orth SR 2003 Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959-967 (Pubitemid 36359277)
11. Siannis F, Copas J, Lu G 2005 Sensitivity analysis for informative censoring in parametric survival models. Biostatistics 6:77-91 (Pubitemid 41240371)
12. Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH 2011 Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22:537-544
13. Brown WW, Collins A, Chen SC, et al 2003 Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program. Kidney Int Suppl S50-S55 (Pubitemid 36126843)
14. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, Flack JM 2003 Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP). Am J Kidney Dis 42:22-35 (Pubitemid 36807651)
15. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M 2012 Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med 172:41-47
16. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA 2011 Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 57:S9-S16
17. Saab G, Whaley-Connell A, Bombeck A, Kurella Tamura M, Li S, Chen SC, McFarlane SI, Sowers JR, Norris K, Bakris GL, McCullough PA 2011 The association between parathyroid hormone levels and the cardiorenal metabolic syndrome in non-diabetic chronic kidney disease. Cardiorenal Med 1:123-130
18. Saab G, Whaley-Connell A, McFarlane SI, Li S, Chen SC, Sowers JR, McCullough PA, Bakris GL 2010 Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism 59:385-389
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461-470 (Pubitemid 29135798)
20. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, SmogorzewskiMT,Slatopolsky EM, McCann L 2004 Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43:558-565 (Pubitemid 38298216)
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J 2009 A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-612
22. 2011 United States Renal Data Systems annual data report. http://www.usrds.org/2011/view/v2-00-appx.asp
23. Fine JP, Gray RJ 1999 A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
24. Tai BC, Wee J, Machin D 2011 Analysis and design of randomised clinical trials involving competing risks endpoints. Trials 12:127
25. Endlich K, Massfelder T, Helwig JJ, Steinhausen M 1995 Vascular effects of parathyroid hormone and parathyroid hormone-related protein in the split hydronephrotic rat kidney. J Physiol 483(Pt 2): 481-490
26. Collier VU, Mitch WE 1980 Accelerated progression of chronic renal insufficiency after parathyroidectomy.JAMA244:1215-1218
27. Rutledge M, Farah V, Adeboye A, Seawell M, Bhattacharya S, Weber K 29 February 2012 Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther 10.1007/s10557-012-6378-0
28. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG 1993 Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 264: H1998-H2006 (Pubitemid 23205973)
29. Borkowski BJ, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT 2011 Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited. Eur Heart J 32:1846-1853
30. Scott PA, Morgan JM, Carroll N, Murday DC, Roberts PR, Peebles CR, Harden SP, Curzen NP 2011 The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators/clinical perspective. Circ Arrhythm Electrophysiol 4:324-330
31. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moysés RM, Jorgetti V 2009 Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant 24:1416-1421
32. Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ 2012 Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 97:132-137
33. Walker MD, Fleischer J, Rundek T, McMahon DJ, Homma S, Sacco R, Silverberg SJ 2009 Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 94:3849-3856
34. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD 2012 Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674-684
35. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, Simon JF, Srinivas TR, Nally Jr JV 2011 Low 25-hydroxyvitamin D levels and mortality in non dialysis-dependent CKD. Am J Kidney Dis 58:536-543
36. López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, de Oca AM, Pineda C, Shalhoub V, Rodríguez M, Aguilera-Tejero E 2011 Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 80:475-482
37. Yee JA 1985 Stimulation of alkaline phosphatase activity in cultured neonatal mouse calvarial bone cells by parathyroid hormone. Calcif Tissue Int 37:530-538 (Pubitemid 15250121)
38. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutírrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St. John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M 2011 FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393-4408
39. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC 2008 Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int 73:1024-1030 (Pubitemid 351543906)
40. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K 2010 Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 25:3003-3011
41. Birkett NJ 1992 Effect of nondifferential misclassification on estimates of odds ratios with multiple levels of exposure. Am J Epidemiol 136:356-362